These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12402424)

  • 1. [Cell therapy for renal cell carcinoma].
    Kawai K
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1745-51. PubMed ID: 12402424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cell therapy in renal cell carcinoma].
    Ravaud A
    Bull Cancer; 2003; 90(8-9):711-21. PubMed ID: 14609761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cellular therapy.
    Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
    Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer.
    Simons JW
    Hinyokika Kiyo; 1997 Nov; 43(11):821-2. PubMed ID: 9436029
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current status of gene therapy clinical studies for renal cell carcinoma].
    Tani K
    Nihon Rinsho; 2005 Mar; 63(3):454-63. PubMed ID: 15773345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte therapy of renal cell carcinoma.
    Dillman RO
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of interleukin-2 in the biotherapy of cancer.
    Parkinson DR
    Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation for renal cell carcinoma.
    Bregni M; Herr W; Blaise D;
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):901-11. PubMed ID: 21707287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
    Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
    Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
    Schwaab T; Tretter C; Gibson JJ; Cole BF; Schned AR; Harris R; Wallen EM; Fisher JL; Waugh MG; Truman D; Stempkowski LM; Crosby NA; Heaney J; Ernstoff MS
    J Urol; 2004 Mar; 171(3):1036-42. PubMed ID: 14767265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
    Yannelli JR; Wroblewski JM
    Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines in renal cell carcinoma.
    Kübler H; Vieweg J
    Semin Oncol; 2006 Oct; 33(5):614-24. PubMed ID: 17045091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
    Harlin H; Artz AS; Mahowald M; Rini BI; Zimmerman T; Vogelzang NJ; Gajewski TF
    Bone Marrow Transplant; 2004 Mar; 33(5):491-7. PubMed ID: 14716341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immune anticancer response: recent advances in the treatment of renal cell carcinoma].
    Bouet F; Catros V
    Ann Biol Clin (Paris); 2004; 62(3):257-68. PubMed ID: 15217758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang.
    Ernstoff MS; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Farnham CJ; Mackay K; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):733s-740s. PubMed ID: 17255302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.